-
In this CME-certified module with accompanying downloadable slideset, Todd M. Bauer, MD, provides expert insights on the biologic role of TRK fusions in cancer along with emerging clinical trial data on TRK-targeted therapies across multiple tumor types.
-
Download these slides on the biologic role of TRK fusions in cancer along with emerging clinical trial data on TRK-targeted therapies across multiple tumor types.
-
Multiple biosimilars are now approved for the treatment of active cancers. Here’s what oncologists need to know.
-
In these downloadable slides, a multidisciplinary panel of expert faculty discuss the use of biosimilars across oncology, rheumatology, dermatology, and gastroenterology specialties.
-
Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, discuss the supporting rationale and emerging role of selective CDK4/6 inhibitors in multiple types of cancer.
|
Latest Content
-
In this CME-certified module with accompanying downloadable slideset, Todd M. Bauer, MD, provides expert insights on the biologic role of TRK fusions in cancer along with emerging clinical trial data on TRK-targeted therapies across multiple tumor types.
Faculty: Todd M. Bauer MD
Released: 4/16/2018
-
Download these slides on the biologic role of TRK fusions in cancer along with emerging clinical trial data on TRK-targeted therapies across multiple tumor types.
Date Posted: 4/16/2018
-
| Hope S. Rugo MD - 1/18/2018 |
|
Multiple biosimilars are now approved for the treatment of active cancers. Here’s what oncologists need to know.
-
In these downloadable slides, a multidisciplinary panel of expert faculty discuss the use of biosimilars across oncology, rheumatology, dermatology, and gastroenterology specialties.
Date Posted: 11/16/2017
-
Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, discuss the supporting rationale and emerging role of selective CDK4/6 inhibitors in multiple types of cancer.
Faculty: Richard Finn MD, Gary K. Schwartz MD, Geoffrey Shapiro MD, PhD
Released: 4/14/2017
-
In this downloadable slideset, Richard Finn, MD, Gary K. Schwartz, MD, and Geoffrey Shapiro, MD, PhD provide insight on the rationale for targeting cyclin dependent kinases 4 and 6 in cancer and highlight emerging clinical data with selective CDK4/6 inhibitors in multiple cancers.
Date Posted: 4/14/2017
-
In this text module and accompanying downloadable slideset, experts review the most clinically relevant study results presented at the 2016 ESMO annual meeting across multiple different malignancies including advanced NSCLC, melanoma, breast cancer, ovarian cancer, and glioblastoma.
Faculty: Margaret Callahan MD, PhD, Shirish Gadgeel MD, Ryan T. Merrell MD, Bradley J. Monk MD, FACS, FACOG, Joyce O'Shaughnessy MD
Released: 1/4/2017
-
In this downloadable slideset, Margaret Callahan, MD, PhD; Shirish Gadgeel, MD; Ryan T. Merrell, MD; Bradley J. Monk, MD, FACS, FACOG; and Joyce O’Shaughnessy, MD, review important clinical presentations across multiple cancers from the 2016 oncology meeting in Copenhagen.
Date Posted: 12/12/2016
-
In these highlights from the ClinicalThought™ program, CCO’s expert faculty members describe how they tackle challenging clinical decisions in the settings of breast cancer, chronic myeloid leukemia, glioblastoma, immune thrombocytopenia, diffuse large B-cell lymphoma, melanoma, multiple myeloma, and prostate cancer.
Faculty: William J. Gradishar MD, FACP, Mohammad Jahanzeb MD, FACP, Elias Jabbour MD, Annick Desjardins MD, FRCPC, David I. Quinn MBBS, PhD, FRACP, FACP, Howard Liebman MD, FACP, Christopher R. Flowers MD, Keith T. Flaherty MD, William I. Bensinger MD, H. Jack West MD
Released: 5/24/2013
-
| Annick Desjardins MD, FRCPC - 1/9/2013 |
8 comments / Last Comment: 7/2/2013 |
New results from a randomized phase III trial show improved PFS and quality of life in newly diagnosed patients with glioblastoma who received bevacizumab and standard therapy. Should we expand our use of bevacizumab into this new setting?
|
|
|